Home
KALV
KALV News

Latest KalVista Pharmaceuticals Inc. (KALV) News on May 11, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 days ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Business Wire

11 days ago

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista licenses commercialisation rights for HAE to Kaken in Japan

Pharmaceutical Technology

a month ago

KalVista licenses commercialisation rights for HAE to Kaken in Japan

MT Newswires

a month ago

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

Business Wire

a month ago

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Business Wire

a month ago

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial

Clinical Trials Arena

2 months ago

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial

MT Newswires

2 months ago

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Business Wire

2 months ago

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Business Wire

2 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Business Wire

2 months ago

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire

2 months ago

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire

3 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire

3 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire

3 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

4 months ago

KalVista Says Japan Health Ministry Grants Orphan Drug Designation to Sebetralstat

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Business Wire

4 months ago

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires

5 months ago

KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

KalVista Appoints Jeb Ledell as Chief Operating Officer

Business Wire

5 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Business Wire

5 months ago

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

Business Wire

6 months ago

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire

6 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Secures $184M Financing for Sebetralstat Launch

TipRanks

6 months ago

KalVista Secures $184M Financing for Sebetralstat Launch

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering

MT Newswires

6 months ago

DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

Business Wire

6 months ago

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

Business Wire

6 months ago

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

Business Wire

6 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

Business Wire

7 months ago

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

Business Wire

7 months ago

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In The United States

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In The United States

MT Newswires

7 months ago

KalVista Submits Marketing Applications for Angioedema Treatment Sebetralstat

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

Business Wire

7 months ago

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

Business Wire

8 months ago

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

MT Newswires

8 months ago

KalVista Pharmaceuticals Names Brian Piekos Finance Chief

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Business Wire

8 months ago

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

KalVista Appoints Brian Piekos as Chief Financial Officer

Business Wire

8 months ago

KalVista Appoints Brian Piekos as Chief Financial Officer

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

Business Wire

8 months ago

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Business Wire

8 months ago

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

KalVista Says New Drug Application for Sebetralstat Accepted by FDA

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Business Wire

8 months ago

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

Business Wire

8 months ago

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Business Wire

9 months ago

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Simply Wall St.

9 months ago

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Business Wire

10 months ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

10 months ago

KalVista Starts Hereditary Angioedema Trial in Pediatric Patients

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Business Wire

10 months ago

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

MT Newswires

a year ago

KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

Business Wire

a year ago

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Business Wire

a year ago

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

Business Wire

a year ago

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

Business Wire

a year ago

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

MT Newswires

a year ago

KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

Business Wire

a year ago

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Simply Wall St.

a year ago

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire

a year ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

Business Wire

a year ago

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

Business Wire

a year ago

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

Business Wire

a year ago

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Business Wire

a year ago

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Business Wire

a year ago

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Business Wire

a year ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

Business Wire

a year ago

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

Business Wire

a year ago

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

Business Wire

a year ago

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

a year ago

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

a year ago

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

Business Wire

a year ago

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Business Wire

a year ago

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

a year ago

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Business Wire

a year ago

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Reuters

a year ago

UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease

Reuters

a year ago

KalVista meets main goals in late-stage trial for skin condition treatment

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Business Wire

a year ago

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Kalvista pill succeeds in late-stage study for rare swelling disorder

BioPharma Dive

a year ago

Kalvista pill succeeds in late-stage study for rare swelling disorder

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Bank of America Is Upbeat, but Preparing for a Worst-Case Outcome

Motley Fool

a year ago

Bank of America Is Upbeat, but Preparing for a Worst-Case Outcome

Is Now An Opportune Moment To Examine Hanesbrands Inc. (NYSE:HBI)?

Simply Wall St.

a year ago

Is Now An Opportune Moment To Examine Hanesbrands Inc. (NYSE:HBI)?

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations

Simply Wall St.

a year ago

First Community Bankshares Full Year 2023 Earnings: In Line With Expectations

Uniti Group Inc. Announces Tax Reporting Information for 2023 Distributions

GlobeNewswire

a year ago

Uniti Group Inc. Announces Tax Reporting Information for 2023 Distributions

Forward Air to Complete Omni Acquisition at Lower Price Tag

The Wall Street Journal

a year ago

Forward Air to Complete Omni Acquisition at Lower Price Tag

BURFORD CAPITAL APPOINTS PAMELA CORRIE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

PR Newswire

a year ago

BURFORD CAPITAL APPOINTS PAMELA CORRIE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

GuruFocus.com

a year ago

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

Share on Social Networks: